Watts Ryan J. 4
4 · Denali Therapeutics Inc. · Filed Jan 8, 2025
Insider Transaction Report
Form 4
Watts Ryan J.
DirectorPresident and CEO
Transactions
- Sale
Common Stock
2025-01-07$20.81/sh−7,650$159,197→ 253,071 total - Sale
Common Stock
2025-01-06$20.22/sh−29,266$591,759→ 260,721 total
Holdings
- 2,202,604(indirect: See footnote)
Common Stock
Footnotes (4)
- [F1]Shares sold to satisfy the tax obligations by the Reporting Person in connection with the settlement of previously vested restricted stock units.
- [F2]The sale price reported in column 4 of Table I represents the weighted average sale price of the shares ranging from $19.91 to $20.23 per share. Upon request by the Commission staff, the Issuer, or a security holder of the Issuer, the Reporting Person will provide full information regarding the number of shares sold at each separate price.
- [F3]Includes 177,940 Unvested RSUs.
- [F4]The shares are held of record by the Watts Family 2015 Trust dated July 7, 2015, for which the Reporting Person serves as trustee.